SCILEX HOLDING CO (SCLX) Stock News

USA - NASDAQ:SCLX - US80880W2052 - Common Stock

16.945 USD

-1.52 (-8.26%)

Last: 11/6/2025, 8:12:35 PM

16.9 USD

-0.05 (-0.27%)

After Hours: 11/6/2025, 8:12:35 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SCLX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Scilex Holding Company

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

4 days ago - By: Scilex Holding Company

Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI

7 months ago - By: Benzinga

What Does the Market Think About Scilex Holding?

a month ago - By: Benzinga - Mentions: IBM DVLT

Datavault AI Stock's Face-Melting 720% Rally—What To Know

a month ago - By: Scilex Holding Company

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

a month ago - By: Scilex Holding Company

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

a month ago - By: Scilex Holding Company

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

a month ago - By: Scilex Holding Company

Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in

a month ago - By: Scilex Holding Company

Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management

a month ago - By: Scilex Holding Company

Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin

2 months ago - By: Scilex Holding Company

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

2 months ago - By: Scilex Holding Company

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination

3 months ago - By: Stocktwits - Mentions: DECA

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

3 months ago - By: Scilex Holding Company

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at

3 months ago - By: Scilex Holding Company

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

5 months ago - By: Scilex Holding Company

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a

5 months ago - By: Scilex Holding Company

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

6 months ago - By: Scilex Holding Company

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional

6 months ago - By: Scilex Holding Company

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional

6 months ago - By: Scilex Holding Company

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

7 months ago - By: Scilex Holding Company

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to

7 months ago - By: Scilex Holding Company

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

7 months ago - By: Scilex Holding Company

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in

7 months ago - By: Yahoo Finance - Mentions: RY RY.CA JPM UBS ...

TD Synnex price target lowered to $145 from $165 at RBC Capital

7 months ago - By: Yahoo Finance - Mentions: RY RY.CA APA SNX ...

Scilex downgraded to Hold from Buy at D. Boral Capital

7 months ago - By: Yahoo Finance - Mentions: IVZ APA SNX SOC ...

Gold and Bonds' Safe Haven Allure May be Fading With Bitcoin Emergence